Loading market dashboard
Aspira Women's Health Inc.
AWHHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, TX AND CLEVELAND, OH / ACCESS Newswire / May 26, 2026 / Aspira Women's Health Inc. (OTCQX:AWHL) ("Aspira" or the "Company"), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women's health, and Cleveland Clinic have signed an agreement to improve women's health diagnostics. Under the terms of this Master Collaboration and License Agreement, Aspira and Cleveland Clinic will collaborate on research projects focused on the discovery and validation of novel biomarker signatures and the development of advanced analytical models intended to improve diagnostic accuracy, clinical utility, and patient care.
Generated Q1 2026 net revenue of $116.9 million and Adjusted EBITDA1 of $26.3 million 51-location footprint to date, with five dispensaries added in 20262 Ranked No. 2 brand house in Illinois, Massachusetts, and New Jersey combined in Q1 20263 Rescheduling poised to unlock immediate and near-term benefits, with potential further impact from follow-on actions NEW YORK, May 13, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today reported its financial results for the quarter ended March 31, 2026 ("Q1 2026").
NEW YORK, April 29, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH-U) (OTCQX: AAWH), a leading, multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced that it will hold a conference call on Wednesday, May 13, 2026, at 5:00 p.m. ET following the release of its first quarter 2026 financial results.
AUSTIN, TX / ACCESS Newswire / April 23, 2026 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease management tools, today announced it is completing the buildout of its molecular laboratory in Q2 2026, marking a major operational milestone that accelerates development and future commercialization of its high-potential endometriosis diagnostic, ENDOinform™. This expansion represents a critical step toward scale, enabling Aspira to advance clinical validation, enhance assay performance, and position the Company for broader market penetration within a multi-billion-dollar diagnostic opportunity.
Delivered Q4 2025 and FY 2025 revenue of $120.5 million and $500.6 million Expanded Adjusted EBITDA Margin 1 to 25.1% in Q4 2025 and 23.4% for FY 2025 Maintained strong liquidity with $ 85.7 million in cash and no significant near-term debt Retail footprint reaches 48 locations as densification continues NEW YORK, March 12, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today reported its financial results for the quarter and year ended December 31, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and all currency is in U.S. dollars.
